Why restrictions on talent mobility and rising trade costs may strengthen India’s position in technology, pharmaceuticals, and global research.
By H. S. Panaser
The United States and India are entering a new phase of economic interdependence, shaped increasingly by immigration restrictions, trade barriers, technological competition and the global search for specialized talent. American policies designed to strengthen domestic employment, encourage manufacturing and reduce dependence on overseas operations are creating a complex set of consequences. While these measures may stimulate investment in selected US industries, they may also encourage multinational corporations to expand sophisticated research, engineering and technology operations in India.
This development presents an important paradox. Policies intended to bring jobs and innovation back to America may, in certain sectors, accelerate India’s emergence as a global innovation hub. The transformation is particularly visible in information technology, artificial intelligence, pharmaceuticals, clinical research and Global Capability Centers (GCCs).
India is no longer merely a destination for low-cost outsourcing. It is increasingly becoming a strategic location for product development, intellectual property creation, advanced analytics, drug research and multinational corporate decision-making. Understanding this shift is essential to evaluating the future of US–India economic relations.
The Changing Economics of Global Talent
American immigration policy has become an important factor in corporate workforce planning. Higher sponsorship costs, uncertainty surrounding skilled-worker visas, evolving H-1B selection rules and employment-based green-card processing constraints can complicate long-term decisions about hiring and retaining international professionals.
The policy objective of protecting American workers is legitimate. The United States must invest in domestic STEM education, technical training and opportunities for its graduates. However, specialized disciplines such as artificial intelligence, semiconductor engineering, medicinal chemistry, biotechnology and advanced software architecture require highly developed skills that cannot always be supplied immediately through domestic recruitment.
When qualified professionals cannot readily relocate to the United States, multinational corporations face several choices: increase domestic compensation, invest in training, delay projects or establish teams where suitable talent is available. Increasingly, India offers an attractive option because of its engineering workforce, established technology ecosystem and growing research infrastructure.
This creates a consequential economic reality: restricting the movement of talent does not necessarily bring the work home; sometimes the work moves to the talent. Instead of transferring engineers and scientists to American headquarters, companies may expand their operations in Bengaluru, Hyderabad, Pune, Chennai and other Indian innovation centers.
Such decisions are not driven by immigration policy alone. They also reflect market access, corporate strategy, available skills and operating costs. Nevertheless, restrictive talent policies can reinforce the business case for developing advanced capabilities outside the United States.
Global Capability Centers: From Cost Savings to Innovation
India’s GCC industry illustrates this transformation. Originally established primarily to deliver support services and reduce operating expenses, many GCCs now perform functions that were previously concentrated near multinational headquarters.
These include AI development, cybersecurity, cloud architecture, advanced engineering, financial analytics, product design, clinical research support, regulatory documentation and enterprise technology strategy.
Industry estimates place India’s GCC sector in the tens of billions of dollars in annual economic activity, with continued expansion expected as more companies establish centers and existing facilities move into higher-value functions. Forecasts suggesting a market exceeding $100 billion should be understood as projections rather than realized revenue.
The significance of this expansion extends beyond employment. GCCs can deepen India’s participation in product design, proprietary research and intellectual property development. Ownership of resulting intellectual property may remain with the multinational parent, but the location of research activity, scientific expertise and technical leadership increasingly matters.
Alongside established GCCs, India is witnessing the development of specialized startups, engineering firms, contract research organizations and technology service providers that function as strategic partners to global corporations. These enterprises can deliver AI applications, software architecture, pharmaceutical analytics and engineering solutions without requiring every specialist to relocate overseas.
The result is an evolving economic model in which India is becoming not simply a provider of technical manpower, but an increasingly important contributor to global innovation.
Artificial Intelligence and the New Geography of Innovation
The growth of GCCs is especially significant for artificial intelligence. As AI becomes central to corporate competitiveness, companies need specialized professionals in machine learning, data engineering, cloud infrastructure, model development and cybersecurity. India’s combination of technical talent established enterprise relationships and expanding digital infrastructure makes it an important destination for these activities.
According to the 2026 Nasscom–Zinnov GCC Landscape Report, India hosted 2,117 GCCs, employing approximately 2.36 million professionals and generating $98.4 billion in annual revenue. The report also identifies AI as a major driver of the industry’s transformation from service delivery toward enterprise innovation.
These figures are important because they demonstrate that India’s innovation ecosystem is no longer an emerging possibility; it is already operating at considerable scale. American corporations can use Indian facilities for global product engineering and research while retaining strategic control of technology platforms and commercial markets. Meanwhile, Indian professionals gain experience in sophisticated technologies, strengthening the country’s capacity to develop its own intellectual property, startups and research enterprises.
Cost remains an advantage, although claims of uniform 60–70 percent savings require caution. Compensation varies substantially by skill, location and employer, while the total cost of a GCC includes infrastructure, management, security, regulatory compliance and coordination. Nevertheless, the combination of competitive operating costs and technical capability provides a strong commercial incentive for continued investment.
Pharmaceuticals: The Economics of Dependence and Resilience
The pharmaceutical sector presents an equally compelling example of US–India interdependence. According to the US Food and Drug Administration, nine out of ten prescriptions dispensed in America are for generic medicines, and approximately 40 percent of those generic products are manufactured in India. (Ref. OGPS)
This dependence has major implications for healthcare affordability and supply security. The Association for Accessible Medicines estimates that generic and biosimilar medicines collectively generated $496 billion in US healthcare savings during 2025. These savings reflect the entire generic and biosimilar market, not Indian manufacturers alone, but they demonstrate why preserving access to affordable medicines remains economically important. (Ref: Association for Accessible Medicines)
American policymakers have valid concerns about reliance on foreign pharmaceutical manufacturing, particularly for essential medicines and active pharmaceutical ingredients (APIs). However, moving pharmaceutical production is far more complicated than relocating an ordinary assembly operation. It requires substantial capital, validated processes, qualified scientific personnel, regulatory approvals and reliable supply chains.
Manufacturing costs in the United States are often higher than in India, particularly for labor-intensive, low-margin generic products. The precise difference depends on the product, technology and production scale. Consequently, wholesale relocation may not be commercially sustainable for every medicine.
A more practical solution is the dual-shore pharmaceutical model, under which Indian and American operations perform complementary functions. India can remain an important center for API production, complex generic synthesis, computational chemistry, clinical data analysis and regulatory documentation. American facilities can provide selected high-priority manufacturing, sterile production, final packaging, distribution, regulatory coordination and strategic inventory capacity.
This approach can improve supply-chain resilience while preserving the economics that make generic medicines affordable.
Major multinational pharmaceutical companies, including Eli Lilly, Bristol Myers Squibb, Pfizer and AstraZeneca, have developed substantial operations or research capabilities in India. Indian pharmaceutical companies such as Sun Pharma, Dr. Reddy’s Laboratories, Zydus and Intas, through Accord Healthcare, have likewise built international commercial and manufacturing networks. These developments reflect a broader industry movement toward geographically distributed research, manufacturing and regulatory capabilities.
For Indian pharmaceutical companies, the next opportunity lies beyond traditional generics. Greater investment in complex formulations, biosimilars, novel drug delivery systems, biotechnology, clinical research and original drug discovery can help India move higher in the pharmaceutical value chain.
Foreign Investment, Trade Barriers and Strategic Autonomy
The expansion of India’s technology and pharmaceutical sectors also has wider implications for foreign direct investment. Multinational corporations deciding where to establish research centers, engineering operations and manufacturing facilities consider not only labor costs but also talent availability, regulatory stability, intellectual property protection, infrastructure and access to markets.
US immigration restrictions may influence these decisions, but it would be misleading to attribute India’s GCC expansion entirely to American visa policies. India’s domestic capabilities, economic growth and long-established corporate relationships have been major drivers of this transformation.
Trade barriers create another consideration. When tariffs or regulatory uncertainties increase the cost of serving one market, companies may diversify their manufacturing and investment locations. India, meanwhile, is strengthening commercial relationships with Europe, the Middle East, Africa and other regions while maintaining its strategic partnership with the United States.
Its participation in BRICS and other international forums reflects a broader commitment to strategic autonomy and multiple economic relationships. This diversification need not weaken US–India cooperation. Indeed, both countries can benefit from supply chains that are more resilient and less dependent on any single geography.
The important distinction is between economic separation and economic diversification. The former seeks to reduce engagement; the latter seeks to manage risk while preserving opportunity.
The Strategic Choice Before Washington and New Delhi
Over the next twenty years, the United States will continue to possess major advantages in advanced research, capital markets, leading universities, biotechnology, semiconductors and frontier technologies. India will bring complementary strengths through its engineering workforce, pharmaceutical manufacturing, expanding domestic market and growing innovation infrastructure.
The central challenge is to turn these complementary capabilities into shared economic value.
For America, this means strengthening domestic education, advanced manufacturing and workforce development while recognizing that access to global talent can support innovation and competitiveness. For India, it means moving beyond labor-cost advantages toward research excellence, intellectual property creation, original innovation and internationally competitive manufacturing.
The Indian diaspora can play an important supporting role. Professionals and entrepreneurs who understand both countries can connect universities, investors, research institutions, technology companies and manufacturers. Such relationships help convert economic opportunities into practical partnerships.
Conclusion: The Cost of Separation
Restrictive immigration policies and trade barriers may achieve certain domestic objectives, but they also carry consequences that extend beyond national borders. When international talent mobility becomes more difficult and operating costs rise, multinational companies reassess where they locate research, engineering and production.
India is increasingly positioned to benefit from those decisions. Its expanding GCC ecosystem, pharmaceutical manufacturing capabilities, scientific workforce and growing AI infrastructure provide a foundation for higher-value investment and innovation.
Yet India’s rise should not be interpreted simply as America’s loss. The two economies remain deeply interconnected. American companies benefit from Indian talent and manufacturing capacity, while Indian enterprises benefit from American capital, technology, research institutions and markets.
The greater risk is not that India will become more innovative. It is that poorly coordinated policies could make cooperation between two complementary economies unnecessarily expensive.
In my assessment, the future of US–India relations should not be defined by a competition to relocate every job, laboratory or manufacturing facility within national borders. It should be defined by a more sophisticated partnership that protects domestic interests while allowing capital, knowledge, technology and enterprise to create value across borders.
The cost of separation may therefore be measured not only in higher corporate expenses or disrupted supply chains, but also in missed opportunities for scientific discovery, affordable healthcare, technological advancement and shared prosperity.
America’s long-term competitiveness and India’s emergence as a global innovation hub need not be opposing objectives. Properly managed, they can become mutually reinforcing pillars of the next generation of US–India economic relations.
PS # This article reflects the author’s independent opinions and analysis, informed by publicly available reports, government publications and industry research. The references are provided for factual context; the interpretations and conclusions remain those of the author.
About the Author: H. S. Panaser is President of the Global Indian Diaspora Alliance (GLO-INDIA) and Chairman of the Global Indian Trade & Cultural Council (GITCC), USA. A former pharmaceutical executive and global business strategist, he writes on international trade, pharmaceuticals, healthcare, technology, AI and diaspora engagement.
Editor’s note: This is an opinion and economic analysis article. The author distinguishes observed investment trends from potential policy consequences. Industry data and regulatory references reflect information available as of October 11, 2026.